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Review: Improving the Therapeutic Index of 8-Aminoquinolines by the Use of Drug
Combinations: Review of the Literature and Proposal for Future Investigations
Hla Y. Myint, Jonathan Berman, Larry Walker, Brandon Pybus, Victor Melendez, J. Kevin Baird, and Colin Ohrt*
Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland; National Center for Natural Products
Research and Department of Pharmacology, School of Pharmacy, University of Mississippi, University, Mississippi; Eijkman–Oxford Clinical
Research Unit, Jalan Diponegoro No. 69, Jakarta, Indonesia; Centre for Tropical Medicine, Nuffield Department of Clinical Medicine,
University of Oxford, Oxford, United Kingdom

Abstract. Because 8-aminoquinolines affect critical survival stages of Plasmodium parasites, treatment and control of
malaria could be markedly improved by more widespread use of these drugs; however, hemolytic toxicity, which is widely
prevalent in G6PD-deficient patients, severely constrains this use. Primaquine was approved more than 50 years ago after
extensive clinical testing. Review of the mid-20th century literature in the light of present understanding of pharmacokinetics and metabolism suggests that manipulation of these factors might dissociate 8-aminoquinoline efficacy from toxicity and lead to an improved therapeutic index.

deficient with 10% to 60% of normal activity (class III), and
very mildly deficient or not deficient with 60% to 100% of
normal activity (class IV).6 G6PD deficiency is X-linked. The
hemizygous male with the common African variant G6PD
A- is typically mildly/moderately deficient with 10–60% of
normal activity.6 In contrast, the hemizygous male with G6PD
Mediterranean variant would be severely affected with < 10%
of normal activity.6 WHO recommendations for primaquine
dosing reflect the need to diminish or avoid the drug depending on the severity of G6PD deficiency. Although daily primaquine is recommended for patients who are G6PD normal,
weekly primaquine is recommended for patients with mild to
moderate G6PD deficiency, and primaquine is contraindicated
for persons with severe G6PD deficiency.2
It is postulated that the efficacy and toxicity of 8aminoquinolines, such as primaquine, are ultimately related to
the generation of reactive oxygen intermediates.7
Primaquine and similar 8-aminoquinolines were developed in the 1940s to 1950s. The literature detailing this work
suggests that the efficacy and toxicity of 8-aminoquinolines
may be modified by coadministration of blood schizonticidal agents. Some of the agents that were used in these combinations are now known to affect enzymes that metabolize
primaquine and other 8-aminoquinolines. We review this literature to suggest methods by which changing 8-aminoquinoline
pharmacokinetic/pharmacodynamic properties might be
attempted. The ultimate aim was to identify a partner drug
that will increase the therapeutic index and thereby, mitigate
the therapeutic constraints of hemolytic toxicity in G6PDdeficient patients.

INTRODUCTION
The 8-aminoquinoline primaquine is a key antimalarial drug
for both Plasmodium falciparum and P. vivax. Primaquine is a
tissue schizontocide that kills early liver stages of P. falciparum
and P. vivax, thereby providing causal prophylaxis against both
infections.1 Antischizontocidal activity can be achieved with a
single dose of 30 mg primaquine within 48 hours of sporozoite inoculation. Primaquine is also the only clinical agent that
kills P. vivax dormant stages (hypnozoites) and P. falciparum
stage 5 gametocytes. The World Health Organization (WHO)
recommendations to eliminate P. vivax hypnozoites and prevent P. vivax relapse are 0.25–0.50 mg/kg per day for 14 days
(for persons with normal glucose 6 phosphate dehydrogenase
[G6PD] levels).2 The recommended regimen to kill P. falciparum gametocytes and prevent transmission is one dose of
0.75 mg/kg.2
The antigametocyte and antirelapse indications are being
increasingly emphasized. For P. falciparum infection in
Myanmar treated with standard blood schizontocidal regimens, patients were randomized to one dose of primaquine
(75 mg base/kg) or no treatment.3 The incidence of gametocytemia was 66 gametocyte-person-weeks per 1,000 weeks of
follow-up in the non-primaquine group versus 5 gametocyteperson-weeks in the primaquine group. In the same study,
there were 69 patients who had recurrences of P. falciparum
infection, but 330 patients had recurrences of P. vivax, including 235 patients who, on the basis of light microscopy, apparently presented only with P. falciparum. A 2011 study on the
Thai–Myanmar border confirmed that, because P. vivax may
be unrecognized in P. falciparum infection, the “most commonly transmitted parasite after treatment for falciparum
malaria, paradoxically, was not P. falciparum, but P. vivax.”4
The use of primaquine for any of these indications is limited, however, by its hemolytic toxicity in G6PD-deficient
patients. At least 200 G6PD genetic variants are known5 and
are classified according to the phenotype. Classes I–IV are,
respectively, completely enzyme deficient with chronic nonspherocytic hemolytic anemia (class I), severely deficiency
with < 10% of normal activity (class II), mildly/moderately

REVIEW OF THE LITERATURE
8-aminoquinolines evaluated in humans. The first 8aminoquinolines to be extensively clinically investigated were
pamaquine and pentaquine. Primaquine was developed in the
1940s7 and is the only 8-aminoquinoline that has been in clinical
use since that time except for quinocide in the former Soviet
Union.8 Tafenoquine can be mentioned as a prominent clinical
agent in present development.7 For patients without the threat
of hemolytic anemia caused by G6PD deficiency, primaquine
dosing is limited by gastrointestinal side effects. Primaquine
replaced pamaquine and pentaquine because of primaquine’s
superior therapeutic index with respect to radical cure versus

* Address correspondence to Colin Ohrt, Division of Experimental
Therapeutics, Walter Reed Army Institute of Research, Silver Spring,
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Figure 1. Clinical 8-aminoquinolines.

gastrointestinal adverse events.9 The structures of pamaquine,
pentaquine, and primaquine are shown in Figure 1.
Augmentation of antirelapse efficacy of 8-aminoquinolines
by coadministration of blood-stage antimalarials. Clinical
experiments in the 1940s and 1950s investigated the efficacy of
8-aminoquinolines alone and combined with blood schizonticidal drugs in preventing relapse (Table 1). Study subjects were
challenged with the Chesson strain of P. vivax through the
bites of infected mosquitoes. After the subject had been febrile
and had parasitemia for a few days, drug was administered to
eliminate blood-stage parasites. The patient was then observed
for recurrence of parasites. The rationale of these experiments
was as follows: if a curative dose of a blood schizonticidal drug
had been administered, any recurrence of parasites constituted
relapse from dormant hypnozoites in the liver. The investigators
validated this approach by showing that blood stage-induced
infections in human volunteers (thereby lacking liver stages)
consistently and completely cleared their infections after
standardized blood schizontocidal therapies without recurrences over long periods of follow-up or risk of reinfection.
Alving and others10 treated patients with quinine alone,
pentaquine alone, or the combination. In all cases, bloodstage parasites disappeared within 6 days. Subsequent para-

site recurrence rates were 92% for quinine alone (data not
shown), 60% for pentaquine alone, and 17% for the combination. The similarity of parasite clearance times and recurrence
times between the groups led Alving and others10 to assume
that, if recurrence of parasites after quinine alone was because
of relapse, recurrence of parasites in the pentaquine groups
would also be because of relapse. In this case, administration
of quinine with pentaquine reduced the relapse rate of pentaquine alone.
Experiments with a sequential design were performed for
quinine and other 8-aminoquinolines. When quinine, which
has a short half-life, was administered several days before
or after an 8-aminoquinoline, the effect on liver stages was
as if each drug had been separately administered. In a small
experiment, all patients given pamaquine followed by quinine relapsed, whereas some patients in whom pamaquine
was administered concurrently with quinine did not relapse.11
When quinine was administered before primaquine, relapse
was seen in 79% of patients, whereas only 5% relapsed when
the two drugs were administered at the same time.12 Another
group of patients received the long half-life drug chloroquine
(1 g) on the first day of primaquine therapy. This group also
showed less relapse (26%) compared with the group in which
primaquine was administered after quinine.
Modification of 8-aminoquinoline toxicity by coadministration of a blood schizonticide. The side effects of
8-aminoquinoline are gastrointestinal reactions, methemoglobinemia, and in persons with G6PD deficiency, mild to severe
intravascular hemolysis.13 Because methemoglobin formation is easily studied and quantified, the occurrence of this
side effect in patients treated with 8-aminoquinolines alone can
be compared with methemolgobinemia in patients treated with
8-aminoquinolines combined with blood schizonticides (Table 1).

Table 1
Modification of 8-aminoquinoline efficacy and toxicity by coadministered drugs
8-AQ

Dose

Efficacy against P. vivax relapse
Pentaquine
60 mg per day × 14 D
Pentaquine
60 mg per day × 14 D
Pamaquine
15 mg per day × 28 D
Pamaquine
15 mg per day × 28 D
Primaquine
15 mg per day × 14 D
Primaquine
15 mg per day × 14 D
Primaquine
15 mg per day × 14 D
Toxicity: MetHgb formation
Pamaquine
30 mg per day × 5-7 D
Pamaquine
30 mg per day × 5-7 D
Pentaquine
60 mg per day × 14 D
Pentaquine
60 mg per day × 14 D
Pentaquine
60 mg per day × 14 D
Pamaquine
31.5 mg per day × 14 D
Pamaquine
31.5 mg per day × 14 D
Primaquine
15 mg per day × 14 D
Primaquine
15 mg per day × 14 D
Primaquine
22.5 mg per day × 14 D
Primaquine
22.5 mg per day × 14 D
Primaquine
30 mg per day × 14 D
Primaquine
30 mg per day × 14 D
Primaquine
60 mg per day × 14 D
Primaquine
60 mg per day × 14 D
Primaquine
120 mg per day × 14 D
Primaquine
120 mg per day × 14 D

Coadministered drug

Dose

Number
subjects/patients

None
Quinine
Quinine
Quinine
Quinine
Quinine
Chloroquine

NA
2 g per day × 14D
2 g per day × 8 D after 8AQ
2 g per day × 28 D with 8AQ
2 g per day × 14 D before 8AQ
2 g per day × 14 D with 8AQ
1 g with first day of 8-AQ

5
47
5
5
19
19
19

None
Quinacrine
None
Quinacrine
Quinine
None
Quinine
None
Quinine
None
Quinine
None
Quinine
None
Quinine
None
Quinine

NA
Not stated
NA
5 g over 14 days
2 g per day × 14 D
NA
2 g per day × 14 D
NA
2 g per day × 14 D
NA
2 g per day × 14 D
NA
2 g per day × 14 D
NA
2 g per day × 14 D
NA
2 g per day × 14 D

29
6
10
5
82
12
27
10
33
16
41
24
8
8
4
5
6

Number relapse (%) or
percent MetHgb (mean)

3 (60%)
8 (17%)
5 (100%)
3 (60%)
15 (79%)
1 (5%)
5 (26%)
4.4
12.2
4.5
12.5
4.3
4.4
4.5
6.1
6.1
10.2
6.8
11.2
8.4
14.7
8.8
20.1
9.9

Ref.

10
10
11
11
12
12
12
14
14
15
15
15
16
16
16
16
16
16
16
16
16
16
16
16

Note that 8-aminoquinoline doses refer to milligrams of base. Quinine doses refer to grams of sulphate. Chloroquine dose refers to grams of base. Quinacrine dose refers to grams of the hydrochloride. 8-AQ = 8-aminoquinoline; D = day; MetHgb = methemoglobin; PQ = primaquine.
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Quinacrine given with an 8-aminoquinoline increased the
amount of methemoglobinemia compared with the amount
that was seen when the 8-aminoquinoline alone was administered. In patients being treated with pamaquine alone or
pamaquine plus quinacrine, the percent methemoglobinemia
after 5–7 days of therapy was 4% for the pamaquine alone
group versus 12% for the combination group.14 When pentaquine was administered alone or with quinacrine, the percent methemoglobin also increased from 4% to 12%.15
In contrast, the combination of quinine and 8-aminoquinolines
did not lead to an increase in percent methemoglobin. No change
between the methemoglobin value for the 8-aminoquinoline
alone versus the combination with quinine was seen for pentaquine15 and pamaquine,16 and for primaquine, combination
with quinine led to an apparent decrease in methemoglobin
in a dose-related fashion.16 In the same work, chloroquine
seemed to have a similar effect in malaria patients but not in
normal volunteers.
We were able to find one study in which hemolysis rather
than methemoglobin formation was the endpoint. Although
this study used pentaquine at a high dose (120 mg/day for
14 days), it is of interest that, in four patients given this dose
alone, there was a mean loss of hemoglobin of 3.2%, whereas
in four patients given this dose plus quinine, the loss of hemoglobin was much diminished at 0.1%.17
These results may be explained on a pharmacokinetic basis
(see below).
Pharmacokinetics and metabolism of the 8-aminoquinolines.
Pamaquine and pentaquine. Sparse information is available
for these old drugs. After oral dosing of pamaquine in humans,
peak serum levels are achieved at approximately 3 hours, and
then, they decline with a half-life of approximately 2 hours.18
Zubrod and others18 also commented that the “pathway of
metabolism of the drug is not known. [There is e]vidence for
the presence of two metabolic intermediates.”18 These two
metabolites were not identified but would likely represent
products of cytochrome P450 or oxidative deamination
pathways. Armer and others19 found that the activity of
pentaquine against coccidian parasites was inhibited by monoamine oxidase inhibitors but not cytochrome P450 inhibitors,19 suggesting that one of the products of this pathway
may mediate the drug’s antiparasitic effect. The importance
of the monoamine oxidase metabolic pathway is becoming
increasingly recognized for primaquine as well (see below).
Primaquine. Absorption is linear over the doses of 15–
45 mg.13 After a 45 mg dose, the time of maximum concentration
is 3 hours and the maximum concentration is 153 ng/mL.13
The mean elimination half-life of primaquine was 4–7 hours
in several studies. Primaquine itself is generally believed
unlikely to be the clinically active form of the drug, because
it is extensively metabolized and less active than some of
its metabolites or derivatives (for example, 4-hydroxy primaquine and 5-hydroxy,6-demethyl primaquine) in in vitro
models.20
The predominant contributors to primaquine metabolism by
human liver microsomes were cytochrome P450 (CPY) 1A2,
2B6, 2D6, and 2E1.21 Elsewhere, primaquine is noted to inhibit
CYPs 1A2, 2D6, and 3A4 and induce CYP 1A2.22 In healthy
volunteers, the maximum concentration of primaquine was
increased by a mean of 23% and area under the curve (AUC)
of 19% when administered with grapefruit juice,23 suggesting
inhibition of intestinal CYP450-mediated metabolism and/

or interaction with transport by P-glycoprotein and organic
anion-transporting polypeptides.24
There is a large body of evidence that primaquine is converted by oxidative deamination to the carboxylic acid
metabolite carboxyprimaquine, which is the predominate species circulating in plasma after oral administration in man.23
Monoamine oxidase (MAO) in mitochondria converts primaquine to primaquine aldehyde, which can then be converted to primaquine alcohol or primaquine carboxylic acid
(carboxyprimaquine).25 Strong evidence for the pathway
primaquine—primaquine aldehyde—carboxyprimaquine was
seen in in vitro cell models.26 Recently, we showed MAO-A
(but not MAO-B) isoenzyme-mediated metabolism of primaquine with the concurrent appearance of masses consistent with carboxyprimaquine formation (Pybus B and others,
unpublished data).
It is evident that primaquine is a substrate for cytochrome
P450-mediated oxidation and also monoamine oxidasemediated metabolism. Both efficacy and hemolysis seem to
depend on metabolic activation of the parent drug, but firm
evidence as to which metabolites mediate efficacy and toxicity
is lacking at present.
Determination of metabolic pathways that lead to efficacy
is difficult, because there is no in vitro model of hypnozoites
within liver cells with which to evaluate efficacy; however,
evaluation of pathways that lead to toxicity in the sense of
methemoglobin formation can be performed. Formation of
methemoglobin by primaquine increased at least 10 times
by coincubating red cells with human liver microsomes, and
this metabolic conversion could also be accomplished by
recombinant human CYPs 1A2, 3A4, 2D6, 2B6, and 2E1.27
Inhibitors of CYPs 2B6, 2D6, and 3A4 caused significant
inhibition of the methemoglobin formation mediated by the
microsomes.
Transport of 8-aminoquinolines into and out of liver cells
seems not to have been investigated, but quinidine is a recognized inhibitor of human P-glycoprotein and organic cation
transporter 1 (quinine also inhibits this transporter) and is a substrate for organic cation transporter 2.28 Intrahepatic or intraparasitic 8-aminoquinoline levels might be modified by changes
in 8-aminoquinoline transport by coadministered drugs.
Potential for drug–drug interaction by combination partners.
Quinine is metabolized largely by CYP 3A4.21 Elsewhere,
quinine is noted to be a substrate of CYPs 1A2 and 2C19
and inhibit CYPs 2C8, 2C9, 2D6, and 3A4.29 Chloroquine is
reported to be metabolized by CYPs 2C8, 2D6, and 3A430 and
inhibit CYP 2D6.31 Quinacrine is metabolized by CYP 3A432
and results in a significant decrease of CYP 2E1 activity and
expression.33
Alterations in pharmacokinetics/metabolism of the 8aminoquinolines by coadministered blood schizonticides.
Pamaquine exposure seems to be increased by the coadministration of quinacrine.18 In four patients, pamaquine concentrations after coadministered drug were at least six times the
level before quinacrine was administered, and the half-lives
approximately quadrupled. Clayman and others16 found a
dose-related decrease in primaquine concentrations with
coadministration with quinine from no apparent effect at
22.5 mg to a 50% reduction at 120 mg primaquine. Edwards and
others34 showed that the conversion of primaquine to a major
but inactive metabolite, carboxyprimaquine, was diminished
in the presence of quinine. The AUC for carboxyprimaquine
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when primaquine alone was administered was 7,533 μg/L-hour
versus 3,831 μg/L-hour when primaquine plus quinine was
administered.34 However, the AUC of primaquine was
unchanged,34 suggesting a shift to a different metabolic
pathway.
DISCUSSION
The antirelapse activity of pentaquine, pamaquine, and primaquine in humans was increased by coadministration of quinine, and the antirelapse activity of primaquine was increased
by chloroquine. Methemoglobin formation because of pentaquine or primaquine was increased by the coadministration of quinacrine but importantly, not by quinine. The overall
data suggest that efficacy and toxicity of 8-aminoquinolines
are modifiable by drug coadministration. Importantly, the quinine data suggest that efficacy and toxicity can be differentially modifiable. The likelihood that these pharmacodynamic
changes reflect altered 8-aminoquinoline metabolism is supported by the changes in pamaquine exposure by quinacrine
and carboxyprimaquine exposure by quinine.
Although active metabolites of primaquine have not been
identified, in vitro studies indicate metabolism of the parent compound by CYPs and monoamine oxidases, especially
monoamine oxidase-A (Pybus B and others, unpublished
data), and perhaps other amine oxidases as well (Walker L
unpublished data). The coadministered drugs quinine, chloroquine, and quinacrine are known substrates or inhibitors of a
wide range of CYPs. Interaction of these coadministered drugs
with amine oxidases and transporters has not been detailed.
We hypothesize that alteration of primaquine pharmacodynamics and pharmacokinetics by drug combinations is based
on competition between the 8-aminoquinoline and coadministered drugs for CYPs, other metabolizing enzymes such as
oxidases, and/or transporters.
We have used methemoglobin formation as a surrogate
marker for red cell toxicity, because methemoglobin seems
to be a consistent hallmark response to 8-aminoquinolines,
and these data are readily available in many clinical studies.
However, hemolysis in G6PD deficiency is the toxicity that
is limiting clinical use, and data are not available on drug
interactions and direct hemolytic risk. There seems to be a
link between hemolysis and methemoglobin formation, both
resulting from the oxidative stress elicited in erythrocytes.
However, the direct mechanistic link is unclear. Most drugs
that cause hemolysis in G6PD-deficient persons also generate
methemoglobinemia, although nitrite causes methemoglobinemia but not hemolysis in this patient population.35
The key reason that little is known about hemolytic toxicity in
G6PD is the lack of preclinical models and the difficulty of conducting clinical studies. The Nonhemolytic 8-Aminoquinoline
Consortium is now qualifying preclinical G6PD mouse models to solve this problem. These models include two qualified
mouse models: a G6PD mutant and a severe combined immunodeficiency (SCID) mouse model in which G6PD-deficient
human red cells are infused into the animal (unpublished
data). A monkey model in which glutathione-depleted Rhesus
red cells are infused back into the animal is also under development. Human studies for evaluation of safety of primaquine
and tafenoquine in G6PD patients are also ongoing and paving the way for assessing drug combinations in the clinic in the
future.

Drug combinations will not be of clinical value if efficacy
and toxicity are increased in tandem. The quinine data lead us
to think that 8-aminoquinoline efficacy and toxicity are caused
by different 8-aminoquinoline metabolites and that efficacy
may be increased without increasing toxicity. To investigate
this hypothesis, we intend to coadminister primaquine with
quinine or chloroquine and with known clinical inducers and
inhibitors of cytochromes, oxidases, and transporters in preclinical efficacy and toxicity models. If we are correct, it may be
possible to increase the therapeutic index of primaquine, and
ultimately tafenoquine, with coadministration of other clinical
agents, and thus may optimize the treatment of malaria with
8-aminoquinolines. With the new models and human capability now available, we hope to substantially impact malaria prevention, control, and elimination.
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